Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Seven Eight Capital LP

Seven Eight Capital LP lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) by 219.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,192 shares of the company’s stock after purchasing an additional 42,034 shares during the period. Seven Eight Capital LP owned about 0.07% of Intellia Therapeutics worth $1,866,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rafferty Asset Management LLC raised its holdings in Intellia Therapeutics by 31.0% in the 4th quarter. Rafferty Asset Management LLC now owns 328,998 shares of the company’s stock valued at $10,031,000 after acquiring an additional 77,873 shares during the last quarter. NEOS Investment Management LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth $936,000. Eagle Asset Management Inc. boosted its position in Intellia Therapeutics by 11.1% in the 4th quarter. Eagle Asset Management Inc. now owns 269,558 shares of the company’s stock valued at $8,219,000 after buying an additional 26,867 shares during the last quarter. Capstone Investment Advisors LLC boosted its position in Intellia Therapeutics by 20.4% in the 4th quarter. Capstone Investment Advisors LLC now owns 59,380 shares of the company’s stock valued at $1,810,000 after buying an additional 10,048 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $318,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 1.0 %

NTLA traded down $0.22 during trading on Friday, hitting $22.73. 1,449,300 shares of the company traded hands, compared to its average volume of 1,671,150. The firm has a market cap of $2.19 billion, a P/E ratio of -4.24 and a beta of 1.84. The stock’s fifty day moving average is $23.70 and its 200 day moving average is $26.92. Intellia Therapeutics, Inc. has a one year low of $19.37 and a one year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NTLA. Wolfe Research started coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. BMO Capital Markets increased their target price on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Canaccord Genuity Group raised their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.77.

Check Out Our Latest Stock Report on Intellia Therapeutics

Intellia Therapeutics Company Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Featured Stories

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.